Skip to main content

What the FDA labels say about taking them together

Eslicarbazepine and omeprazole

Eslicarbazepine's FDA label of November 10, 2023 names omeprazole in its drug interactions section; the omeprazole labels PlainMeds reads (2) do not name eslicarbazepine. The eslicarbazepine label: “CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme.”

Check it at the source: the eslicarbazepine FDA label on DailyMed (effective November 10, 2023, Sumitomo Pharma America, Inc.); the omeprazole FDA label on DailyMed (effective April 22, 2024, Apotex Corp).

What does the eslicarbazepine label say about omeprazole?

Eslicarbazepine label, drug interactions

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )].

Source: FDA drug label (Aptiom), Sumitomo Pharma America, Inc., effective November 10, 2023 (SPL set 3d0c9554-eaeb-4694-8089-00133fcadce3), via openFDA; the full label on DailyMed

What does the omeprazole label say about eslicarbazepine?

Omeprazole's label (effective April 22, 2024) and its 1 other brand-application label do not name eslicarbazepine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Omeprazole), Apotex Corp, effective April 22, 2024 (SPL set b83329ac-a65e-b3af-a3fb-c5a6c740e5e7), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

9Eslicarbazepine generic labelers
118Omeprazole generic labelers
EslicarbazepineOmeprazole
Labeled forSeizures and epilepsyAcid reflux and ulcers
Boxed warningNoNo
Pharmacy cost (NADAC)$1.68 per tablet 200 mg tablet$0.0295 per capsule 20 mg capsule
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?